Global pharmaceutical company Pfizer has announced the launch of a Rimegepant Orally Disintegrating Tablet (ODT) in India for acute treatment of migraine in adults with a previous insufficient ...

Pfizer has launched Rimegepant ODT, a new migraine treatment in India. It offers rapid, lasting relief and targets patients who do not respond to conventional drugs. The medication dissolves without ...

Migraine is a growing public health concern in India. According to a study published in The Journal of Headache and Pain, nearly 26.3% of people in Delhi NCR suffer from the condition. Pfizer on ...

Pfizer launches new migraine drug in India (Image Source: Freepik) Drug maker Pfizer on Monday introduced a new migraine treatment in India, offering hope to millions who struggle with severe and ...

AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up with main rivals Pfizer/BioHaven and their ...

Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this year as an acute treatment. The ...

What Is SEC Form D? SEC Form D is required for companies selling securities under Regulation (Reg) D or Section 4(a)(5) exemptions. Form D provides basic information about the company for investors.

One in 5 of the highest-revenue drugs of 2022 was exclusively approved for rare conditions, accounting for more than 7% of US pharmaceutical spending. Study Design: Cross-sectional study. Methods: ...